Corcept Therapeutics
CORT
49 hedge funds and large institutions have $108M invested in Corcept Therapeutics in 2013 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 13 closing their positions.
91% more capital invested
Capital invested by funds: $56.7M → $108M (+$51.7M)
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
16% less funds holding
Funds holding: 58 → 49 (-9)
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ISL
Ingalls & Snyder LLC
New York
|
+$445K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$125K |
| 3 |
Morgan Stanley
New York
|
+$115K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$111K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Eagle Investment Management
New York
|
-$3.04M |
| 2 |
SCA
SAC Capital Advisors
Stamford,
Connecticut
|
-$795K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$200K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$191K |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
-$155K |
CORT Hedge Fund Activity: Q4 2013 in Review
49 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q4 2013, worth a combined $108M — up 91% from $56.7M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of CORT and 4 opened new positions — a net loss of 9 holders — while 14 trimmed existing stakes and 17 added.
The largest buyer was Ingalls & Snyder LLC, adding an estimated $445K. The largest seller was First Eagle Investment Management, cutting an estimated $3.04M.
- 49 institutional investors held Corcept Therapeutics (CORT) as of Q4 2013, down from 58 in Q3 2013.
- Funds reported $108M of Corcept Therapeutics stock for Q4 2013, up 91% quarter-over-quarter.
- 4 funds opened new Corcept Therapeutics positions in Q4 2013 and 13 closed out, a net change of -9 holders.
- The largest Corcept Therapeutics buyer in Q4 2013 was Ingalls & Snyder LLC, an estimated $445K added.
- The largest Corcept Therapeutics seller in Q4 2013 was First Eagle Investment Management, an estimated $3.04M sold.
Based on aggregated 13F filings for Q4 2013.